SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

PR Newswire

NEW YORK, Jan. 27, 2022

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to:

https://www.zlk.com/pslra-1/revance-therapeutics-inc-information-request-form?prid=22613&wire=4

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500.There is no cost or obligation to you.

Revance Therapeutics, Inc. NEWS - RVNC NEWS

CASE DETAILS: According to the filed complaint: (i) quality control deficiencies existed at the Company's manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Revance, you have until February 8, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Revance securities between November 25, 2019 and October 11, 2021, you may be entitled to compensation without payment of any out-of-pocket costs or fees.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/revance-therapeutics-inc-information-request-form?prid=22613&wire=4 or call 212-363-7500 to discuss the case with Joseph E. Levi, Esq.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-shareholders-of-revance-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-8-2022--rvnc-301470058.html

SOURCE Levi & Korsinsky, LLP